| 5.73 -0.295 (-4.9%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.38 |
1-year : | 9.61 |
| Resists | First : | 7.17 |
Second : | 8.22 |
| Pivot price | 5.96 |
|||
| Supports | First : | 5.48 | Second : | 4.55 |
| MAs | MA(5) : | 5.95 |
MA(20) : | 5.95 |
| MA(100) : | 6.15 |
MA(250) : | 6.04 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 30.4 |
D(3) : | 34.3 |
| RSI | RSI(14): 45.3 |
|||
| 52-week | High : | 9.82 | Low : | 3.27 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ VRCA ] has closed above bottom band by 31.5%. Bollinger Bands are 74.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.21 - 6.25 | 6.25 - 6.27 |
| Low: | 5.58 - 5.62 | 5.62 - 5.65 |
| Close: | 5.81 - 5.87 | 5.87 - 5.92 |
Verrica Pharmaceuticals Inc. is a US-based pharmaceutical company dedicated to developing and commercializing therapeutic solutions for various skin diseases. Its primary investigational compound, VP-102, has successfully completed Phase II clinical trials for molluscum contagiosum and external genital warts, and is presently in Phase II development for common warts. Additionally, the company is advancing VP-103, a cantharidin-based product candidate, designed to treat plantar warts. Verrica maintains a strategic license and collaboration agreement with Torii Pharmaceutical Co., Ltd., focusing on the development and commercialization of its product candidates, including VP-102, for molluscum contagiosum and common warts in the Japanese market. Furthermore, a separate licensing agreement with Lytix Biopharma AS allows for the development and commercialization of LTX-315 for dermatological oncology applications. Verrica Pharmaceuticals Inc. was established in 2013 and has its headquarters in West Chester, Pennsylvania.
Tue, 09 Jun 2026
Director at Verrica (NASDAQ: VRCA) receives 16,000 stock options - Stock Titan
Tue, 09 Jun 2026
Verrica (VRCA) director Diem Nguyen awarded 16,000 stock options at $6.04 - Stock Titan
Tue, 09 Jun 2026
Verrica Pharmaceuticals (NASDAQ: VRCA) director awarded 16,000 stock options at $6.04 - Stock Titan
Tue, 09 Jun 2026
Verrica (VRCA) CMO receives 233,840 performance-vested stock options - Stock Titan
Tue, 09 Jun 2026
Verrica (VRCA) CEO awarded 512,269 options with $15 and $25 vesting hurdles - Stock Titan
Thu, 28 May 2026
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 17 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 48.6 (%) |
| Held by Institutions | 27.8 (%) |
| Shares Short | 412 (K) |
| Shares Short P.Month | 581 (K) |
| EPS | -1.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.44 |
| Profit Margin | -48 % |
| Operating Margin | -193.5 % |
| Return on Assets (ttm) | -20.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 46 % |
| Gross Profit (p.s.) | 1.32 |
| Sales Per Share | 2.16 |
| EBITDA (p.s.) | -0.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -5.34 |
| PEG Ratio | 0 |
| Price to Book value | 4.07 |
| Price to Sales | 2.71 |
| Price to Cash Flow | -7.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|